Nilüfer Ertekin‐Taner

This paper identifies APOE-ϵ4-induced fibronectin accumulation at the blood-brain barrier as a key mediator of astrocyte-endothelial dysfunction in Alzheimer's disease, highlighting it as a potential therapeutic target.

The paper identifies epigenetic changes in Alzheimer's disease brains linked to tau pathology, highlighting oligodendrocyte gene perturbations as a potential common mechanism across tauopathies.

The paper identifies distinct protein interactors of Tau-seed in AD across species and brain regions, highlighting functional differences in Tau propagation.

This study identifies genetic risk factors for FTLD-TDP subtypes using whole-genome sequencing and meta-analysis across multiple cohorts.

This study identifies cell-type-specific druggable targets in Alzheimer's disease by integrating GWAS and eQTL data across multiple cell types and datasets.

The paper performs large-scale proteomic analysis of Alzheimer's disease brain regions across different racial and ethnic groups, identifying AD-related protein changes and APOE4 concordance with genotype.

This paper presents a multi-omics dataset from multi-ethnic Alzheimer's disease brain donors, including transcriptome, genome, and proteome data, to improve precision medicine for underrepresented populations.

This study identifies ABCA7-dependent neuropeptide Y signaling as a resilience mechanism critical for synaptic integrity and its disruption as a risk factor for Alzheimer's disease.

The paper identifies a conserved Aβ amyloid 'responsome' in human and mouse AD brains, showing how amyloid scaffolds proteins involved in disease pathology.

This study investigates changes in the UFMylation pathway in Alzheimer's disease brains, finding increased UFM1 conjugation and associations with pathological tau.

The paper identifies rare FN1 variants that protect APOEε4 carriers from Alzheimer's disease by modulating extracellular matrix deposition and gliosis.

The paper shows that Ngfr promotes neurogenesis and reduces amyloid pathology in AD mouse models by suppressing Lcn2/Slc22a17 signaling.

This study identifies novel Alzheimer's disease risk loci by analyzing multi-ancestry GWAS data from diverse populations, highlighting the importance of including underrepresented groups in genetic research.

This study performs a genome-wide association study of brain biochemical phenotypes in Alzheimer's patients, identifying novel genetic loci and highlighting distinct genetic architectures for AD-related proteins.

The paper identifies JMJD6 and other key drivers of Alzheimer's disease using predictive network analysis and validates their effects on amyloid-beta and tau pathology in human neurons.

The paper identifies key driver genes for microglial phagocytosis and repurposes riluzole to treat Alzheimer's Disease by enhancing SLC1A2 activity.

This study shows that deletion of Abi3/Gngt2 affects amyloid β and tau pathologies differently with age in AD models.

This study identifies widespread metabolic dysregulation in Alzheimer's disease brain tissue, linking it to tau pathology and highlighting potential pathomechanisms.

The paper identifies three novel immune pathway genes with deleterious variants associated with Alzheimer's disease using polygenic risk scores in whole exome sequence data.

This study identifies blood-based biomarkers associated with Alzheimer's disease genetic risk variants in a large cohort of healthy adults, showing effects from early adulthood and sex-specific patterns.

The paper uses single nucleus RNA sequencing to analyze brain vascular cells in Alzheimer's disease, identifying molecular changes and interactions between vascular and astrocytic cells at the blood-brain barrier.

The paper compares microglial transcriptomic responses to Aβ peptide aggregates ex vivo and in vivo, finding distinct responses and highlighting the limitations of using ex vivo models to predict in vivo behavior.

The paper characterizes human microglia transcriptomes and identifies gene expression signatures linked to age, sex, and APOE-ε4, revealing immunometabolic pathway perturbations in neurodegeneration.

The paper identifies SERPINA5 as a novel tau binding partner in Alzheimer's disease by analyzing hippocampal gene expression and neurofibrillary tangles.

The paper identifies an epigenomic factor linked to reduced activated microglia that mitigates the risk of Alzheimer's disease in APOE ε4 carriers.

The paper estimates molecular pseudotime for Alzheimer's disease progression using RNA-Seq data from human brain samples, showing strong concordance with pathological markers and cognitive diagnosis.

The paper identifies four genes, including two novel ones, co-expressed with TREM2 in Alzheimer's disease using whole-exome data from ADSP.

The paper develops a workflow to identify transcription factor binding sites across 27 human tissues using DNase-seq data, resulting in a comprehensive footprint atlas with high-quality predictions.